Taiwan, China, 27 January 2021 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received a medical device license from the Taiwan Ministry of Health and Welfare (MOHW) for its proprietary coronary balloon dilatation catheter, Firefighter™ NC.

Firefighter™ NC is a new generation of high-pressure resistant and rapid exchange balloon dilatation catheters developed by MicroPort®, that follow its predecessor, Foxtrot™ NC. It is designed for balloon dilatation of stenoses in coronary tracts or coronary bypass bridges to improve myocardial perfusion. It is also used in post-balloon dilatation of stents after their implantation.

The outer surface of the catheter is coated with a hydrophilic polymer from the front and rear attachment points to the distal end of the product, which reduces friction on the surface of the catheter when combined with water during a surgery, thereby facilitating catheter's delivery into and across lesions.

The market approval of Firefighter™ NC further broadens the coronary product portfolio of MicroPort® in Taiwan, China. As the Firehawk® Rapamycin Target Eluting Coronary Stent System, Firefighter™, and the Coronary Balloon Dilatation Catheter (Firefighter™ NC) successively enter the Taiwan market, MicroPort® is gaining influence and market share in the local market. In the future, MicroPort® will continue to expand the Taiwan market and provide local patients and doctors with high quality, universally accessible medical products and services.[PER1]

[PER1] If possible, consider attributing this sentence to a MicroPort spokesperson.

Attachments

  • Original document
  • Permalink

Disclaimer

MicroPort Scientific Corporation published this content on 27 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 January 2021 15:47:01 UTC.